NR 546 PSYCHOPHARMACOLOGY PMHNP MIDTERM EXAM
2026/2027 | Questions and Verified Answers |
Psychiatric-Mental Health Nurse Practitioner Prep | Pass
Guaranteed - A+ Graded
Basic Principles of Psychopharmacology (PK/PD, Neurobiology)
Q1: A 32-year-old patient with depression is started on fluoxetine 20mg daily. The
PMHNP explains that steady-state plasma concentrations will typically be reached after
approximately how many days, given fluoxetine's long half-life?
A. 3-5 days
B. 7-10 days
C. 2-4 weeks
D. 4-6 weeks
Correct Answer: C
Rationale: Fluoxetine has a long half-life (1-3 days for fluoxetine, 4-16 days for active
metabolite norfluoxetine). Steady-state is reached in approximately 2-4 weeks (5
half-lives). Option A is too short for any SSRI. Option B is typical for shorter half-life
,SSRIs like sertraline. Option D is longer than needed for steady-state (though
therapeutic effects may take this long).
Q2: A PMHNP is prescribing a medication that is a CYP2D6 substrate. The patient is a
known CYP2D6 poor metabolizer based on pharmacogenomic testing. What is the
clinical implication?
A. The patient will require higher doses to achieve therapeutic effect
B. Standard dosing is appropriate as genotype does not affect drug metabolism
C. The patient is at increased risk for adverse effects and toxicity with standard dosing
D. The medication will have decreased bioavailability
Correct Answer: C
Rationale: CYP2D6 poor metabolizers have reduced or absent enzyme activity, leading
to slower metabolism, higher drug levels, and increased toxicity risk with standard
doses. Option A describes ultra-rapid metabolizers. Option B is false—genotype
significantly affects metabolism. Option D confuses metabolism with absorption.
,Q3: A patient taking carbamazepine for bipolar disorder notices that the medication
seems less effective after several months. Serum levels show decreased concentration
despite adherence. This phenomenon is best explained by:
A. Tolerance to the therapeutic effects
B. Autoinduction of CYP3A4 metabolism
C. Increased protein binding
D. Decreased renal clearance
Correct Answer: B
Rationale: Carbamazepine induces its own metabolism (autoinduction) through
CYP3A4, requiring dose increases over the first 4-6 weeks. Option A describes reduced
pharmacodynamic response. Option C would increase free drug. Option D is
irrelevant—carbamazepine is hepatically metabolized.
Q4: A medication has high lipophilicity and crosses the blood-brain barrier easily. Which
pharmacokinetic property does this describe?
A. High first-pass metabolism
B. Good CNS penetration
, C. Low volume of distribution
D. High renal clearance
Correct Answer: B
Rationale: Lipophilicity facilitates crossing the blood-brain barrier, enabling CNS
penetration—essential for psychiatric medications. Option A relates to hepatic
extraction before systemic circulation. Option C is opposite—lipophilic drugs typically
have high Vd. Option D is incorrect—lipophilic drugs are metabolized, not renally cleared.
Q5: A patient asks why their sertraline prescription warns about taking with grapefruit
juice. The PMHNP explains that grapefruit juice:
A. Increases gastric acid secretion, destroying the medication
B. Inhibits intestinal CYP3A4, increasing bioavailability of some medications
C. Induces CYP2D6, decreasing drug levels
D. Binds to the medication in the gut, preventing absorption
Correct Answer: B
2026/2027 | Questions and Verified Answers |
Psychiatric-Mental Health Nurse Practitioner Prep | Pass
Guaranteed - A+ Graded
Basic Principles of Psychopharmacology (PK/PD, Neurobiology)
Q1: A 32-year-old patient with depression is started on fluoxetine 20mg daily. The
PMHNP explains that steady-state plasma concentrations will typically be reached after
approximately how many days, given fluoxetine's long half-life?
A. 3-5 days
B. 7-10 days
C. 2-4 weeks
D. 4-6 weeks
Correct Answer: C
Rationale: Fluoxetine has a long half-life (1-3 days for fluoxetine, 4-16 days for active
metabolite norfluoxetine). Steady-state is reached in approximately 2-4 weeks (5
half-lives). Option A is too short for any SSRI. Option B is typical for shorter half-life
,SSRIs like sertraline. Option D is longer than needed for steady-state (though
therapeutic effects may take this long).
Q2: A PMHNP is prescribing a medication that is a CYP2D6 substrate. The patient is a
known CYP2D6 poor metabolizer based on pharmacogenomic testing. What is the
clinical implication?
A. The patient will require higher doses to achieve therapeutic effect
B. Standard dosing is appropriate as genotype does not affect drug metabolism
C. The patient is at increased risk for adverse effects and toxicity with standard dosing
D. The medication will have decreased bioavailability
Correct Answer: C
Rationale: CYP2D6 poor metabolizers have reduced or absent enzyme activity, leading
to slower metabolism, higher drug levels, and increased toxicity risk with standard
doses. Option A describes ultra-rapid metabolizers. Option B is false—genotype
significantly affects metabolism. Option D confuses metabolism with absorption.
,Q3: A patient taking carbamazepine for bipolar disorder notices that the medication
seems less effective after several months. Serum levels show decreased concentration
despite adherence. This phenomenon is best explained by:
A. Tolerance to the therapeutic effects
B. Autoinduction of CYP3A4 metabolism
C. Increased protein binding
D. Decreased renal clearance
Correct Answer: B
Rationale: Carbamazepine induces its own metabolism (autoinduction) through
CYP3A4, requiring dose increases over the first 4-6 weeks. Option A describes reduced
pharmacodynamic response. Option C would increase free drug. Option D is
irrelevant—carbamazepine is hepatically metabolized.
Q4: A medication has high lipophilicity and crosses the blood-brain barrier easily. Which
pharmacokinetic property does this describe?
A. High first-pass metabolism
B. Good CNS penetration
, C. Low volume of distribution
D. High renal clearance
Correct Answer: B
Rationale: Lipophilicity facilitates crossing the blood-brain barrier, enabling CNS
penetration—essential for psychiatric medications. Option A relates to hepatic
extraction before systemic circulation. Option C is opposite—lipophilic drugs typically
have high Vd. Option D is incorrect—lipophilic drugs are metabolized, not renally cleared.
Q5: A patient asks why their sertraline prescription warns about taking with grapefruit
juice. The PMHNP explains that grapefruit juice:
A. Increases gastric acid secretion, destroying the medication
B. Inhibits intestinal CYP3A4, increasing bioavailability of some medications
C. Induces CYP2D6, decreasing drug levels
D. Binds to the medication in the gut, preventing absorption
Correct Answer: B
